As of 3:59pm ET
| +0.03 / +4.23%|
DARA BioSciences, Inc. is a pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company's product portfolio includes Soltamox, Gelclair, Bionect and KRN5500. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. The company markets Bionect, a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. DARA BioSciences was founded by Steven Gorlin on June 22, 2002 and is headquartered in Raleigh, NC.
|David J. Drutz||Executive Chairman & Chief Medical Officer|
|Christopher G. Clement||President, Chief Executive Officer & Director|
|David L. Tousley||Chief Financial Officer & Executive Vice President|
|Mary Kay Delmedico||Vice President-Scientific & Regulatory Affairs|
|Michael Radomsky||Vice President-Technical Operations|